Stockscreener 앱 받기
21.73
1.90%
-0.42
시간 외 거래:
21.85
0.12
+0.55%
Sarepta Therapeutics Inc 주식(SRPT)의 최신 뉴스
Sarepta Therapeutics (SRPT) price target decreased by 10.97% to 22.48 - MSN
Chipmakers Recap: Can Sarepta Therapeutics Inc deliver consistent EPS growth2026 Macro Moves & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Stock Report: Is Sarepta Therapeutics Inc vulnerable to short sellersRecession Risk & Fast Gain Stock Tips - baoquankhu1.vn
Why is Sarepta Therapeutics (SRPT) up 24.2% since last earnings report? - MSN
Sarepta drops as report suggests FDA needs new trials for Elevidys - MSN
Sarepta Therapeutics (SRPT) price target decreased by 16.58% to 25.25 - MSN
Sarepta plans FDA filings seeking full approval for two DMD therapies - MSN
Sarepta Therapeutics, Inc. (SRPT) stock price, news, quote and history - Yahoo Finance Singapore
Sarepta Therapeutics, Inc. (SRPT) Stock Forecasts - Yahoo Finance
Sarepta Therapeutics, Inc. (AB3A.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
SRPT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
A decade ago, these drugs tore apart the FDA. Today, they might be some patients' best hope - statnews.com
Antisense Oligonucleotides Market 2026-2033 | US$ 5,286.96 - openPR.com
Sarepta Therapeutics, Inc. (SRPT) Stock Price, News, Quote & History - ca.finance.yahoo.com
Sarepta siRNA Data Adds New Pillar To Rare Disease Pipeline Narrative - Yahoo Finance
Is Sarepta Therapeutics (SRPT) Starting To Look Interesting Again After Recent Share Price Rebound - Sahm
TD Cowen Downgrades Sarepta Therapeutics (SRPT) Stock to Hold, Reduces PT - MSN
9 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
RBC Adjusts Price Target on Sarepta Therapeutics to $19 From $18, Maintains Sector Perform Rating - Moomoo
How The Sarepta Therapeutics (SRPT) Investment Story Is Shifting On Mixed Elevidys And Pipeline Views - Yahoo Finance
Trading the Move, Not the Narrative: (SRPT) Edition - Stock Traders Daily
Duchenne Muscular Dystrophy Therapeutics Market to Reach USD - openPR.com
Income Plays: What is the PEG ratio of Sarepta Therapeutics Inc2026 PreEarnings & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Sarepta Therapeutics (SRPT) Is Up 16.3% After Early siRNA Muscle Data Validates Avß6 Platform - Sahm
Aberdeen Group Boosts Stake in Sarepta Therapeutics - National Today
Aberdeen Group plc Increases Stake in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
The Precedent: Federal Circuit Upholds Gene Therapy Host Cell Claims Under 35 U.S.C. § 101 in Regenxbio Inc., Et Al. v. Sarepta Therapeutics, Inc., Et Al. - JD Supra
SG Americas Securities Trims Sarepta Therapeutics Stake - National Today
SG Americas Securities LLC Lowers Holdings in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta gets New Zealand approval for Huntington’s disease trial - Investing.com
Sarepta Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
SAREPTA THERAPEUTICS INC (1SRPT.MI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wealth Enhancement Advisory Services LLC Acquires 62,981 Shares of Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Wells Fargo Remains a Buy on Sarepta Therapeutics (SRPT) - The Globe and Mail
Sarepta Therapeutics, Inc. (SRPT) Stock forecasts - uk.finance.yahoo.com
SRPT Stock Price, Quote & Chart | SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) - ChartMill
Sarepta Therapeutics, Inc. (0L35.L) Stock Price, News, Quote & History - Yahoo! Finance Canada
Charcot-Marie-Tooth (CMT) Disease Market Size to Reach US$ - openPR.com
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
2.69%
0.25%
자본화:
|
볼륨(24시간):